Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

IGF-1 LR3 vs IGF-1 DES

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

This combination is flagged

Two IGF-1 analogs in the same regimen: Moderate-High risk per peptide research literature. Multiple IGF-1 analogs compete for the same IGF-1R pool; the second analog does not raise peak receptor activation but stacks hypoglycemia exposure, cardiac/renal/hepatic hypertrophy signal, and peripheral neuropathy risk in heavy stacks.

Data-derived verdict

IGF-1 LR3 and IGF-1 DES share the igf-1 class and carry roughly equivalent evidence (Anecdotal + Animal Studies / Anecdotal + Animal Studies). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

IGF-1 LR3

Anecdotal + Animal Studies

IGF-1 DES

Anecdotal + Animal Studies

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Shared safety considerations

Both compounds share these reported concerns: theoretical cancer risk. Open each peptide page for the full risk paragraph and source citations.

Side-by-side

IGF-1 LR3 IGF-1 DES
Class IGF-1 analog (extended half-life); anabolic IGF-1 analog (truncated); anabolic
Drug class Growth Hormone Secretion Growth Hormone Secretion
Mechanism IGF-1 receptor agonist; Arg3 substitution reduces IGFBP binding for prolonged activity Truncated IGF-1 with reduced IGFBP binding for higher local receptor activity
Route SC / IM SC / IM
Half-life ~20-30 hrs ~30 min
Dosage (research) 20 mcg SC daily (Seeds Vol 1 endurance and recovery starting dose, range up to 100 mcg/day for hypertrophy per r/Peptides wiki) 50-150 mcg SC near target muscle
Evidence tier Anecdotal + Animal Studies Anecdotal + Animal Studies
Research depth 34 indexed (PubMed 15 · CT 0 · EPMC 19) 25 indexed (PubMed 13 · CT 0 · EPMC 12)
Availability Research Chemical Research Chemical
Reported risks Hypoglycemia risk; theoretical cancer risk; disproportional organ/tissue growth Hypoglycemia; localized tissue growth; theoretical cancer risk

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick IGF-1 LR3 or IGF-1 DES?

IGF-1 LR3 and IGF-1 DES share the igf-1 class and carry roughly equivalent evidence (Anecdotal + Animal Studies / Anecdotal + Animal Studies). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.

What is the difference between IGF-1 LR3 and IGF-1 DES?

IGF-1 LR3 is classed as IGF-1 analog (extended half-life); anabolic; IGF-1 DES is classed as IGF-1 analog (truncated); anabolic. Reported mechanism: IGF-1 LR3, IGF-1 receptor agonist; Arg3 substitution reduces IGFBP binding for prolonged activity; IGF-1 DES, Truncated IGF-1 with reduced IGFBP binding for higher local receptor activity. Reported half-life: IGF-1 LR3, ~20-30 hrs; IGF-1 DES, ~30 min. Routes in published studies: IGF-1 LR3, SC / IM; IGF-1 DES, SC / IM.

Which has stronger evidence, IGF-1 LR3 or IGF-1 DES?

IGF-1 LR3 and IGF-1 DES sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. IGF-1 LR3 is graded Anecdotal + Animal Studies, with 2 cited sources on its reference page and 34 indexed studies. IGF-1 DES is graded Anecdotal + Animal Studies, with 2 cited sources on its reference page and 25 indexed studies.

Which is more accessible, IGF-1 LR3 or IGF-1 DES?

Neither IGF-1 LR3 nor IGF-1 DES is an FDA-approved drug. Catalog status: IGF-1 LR3, Research Chemical; IGF-1 DES, Research Chemical.

Are IGF-1 LR3 and IGF-1 DES ever combined?

IGF-1 LR3 and IGF-1 DES appear together in no stack catalogued on PeptideHelper.org. PeptideHelper.org's interaction engine flags the pair: Two IGF-1 analogs in the same regimen, moderate-high risk.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…